Volatility Grows in Biotech Sector -- Keryx and AVI BioPharma Need to Put Up Results

   Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Bedford Report examines investing opportunities in the Biotechnology Industry and provides equity research on Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) and AVI BioPharma Inc. (NASDAQ: AVII). Access to the full company reports can be found at:

www.bedfordreport.com/KERX

www.bedfordreport.com/AVII

While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

The Bedford Report releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Keryx Biopharmaceuticals said that an independent monitoring board recommended that its late-stage study of a potential colorectal cancer treatment continue as planned until it is completed. The company is studying perifosine in patients with an advanced form of the disease. The study has enrolled more than 465 patients nationwide, and it will measure the safety and effectiveness of perifosine plus another treatment, capecitabine, compared to a combination of a placebo and capecitabine in people who have had a previous treatment fail.

AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. For the second quarter of 2011 AVI reported an operating loss of $10.1 million compared with an operating loss of $7.7 million in the second quarter of 2010.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: The Bedford Report Email Contact